Aclaris therapeutics reports third quarter 2023 financial results and provides a corporate update

- topline data from zunsemetinib phase 2b trial in rheumatoid arthritis expected this month – - completion of enrollment in ati-1777 phase 2b trial in atopic dermatitis as previously announced; topline data anticipated around year-end 2023 - wayne, pa., nov. 06, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking